Triptorelin

Generic Name: Triptorelin

Brand Names: Decapeptyl, Trelstar, Triptodur

Drug Type: Small Molecule

Chemical Formula: C_₆₄H_₈₂N_₁₈O_₁₃

CAS Number: 57773-63-4

Unique Ingredient Identifier: 9081Y98W2V

Background: Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.

Indication: Triptorelin is indicated for the palliative treatment of advanced prostate cancer.

Associated Conditions: Advanced Prostate Cancer

Associated Therapies: Controlled ovarian hyperstimulation therapy

Clinical Trials

The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies

Phase 4

Completed

Conditions: Sterility
Infertility

Interventions: Drug: Triptorelin

First Posted Date: 2017-05-30

Last Posted Date: 2023-07-20

Lead Sponsor: American University of Beirut Medical Center

Target Recruit Count: 277

Registration Number: NCT03169166

Locations: 🇱🇧
American University of Beirut Medical Center, Beirut, Lebanon

Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI

Phase 4

Completed

Conditions: Invitro Fertilization

Interventions: Drug: Triptorelin
Drug: cetrorelix
Drug: Recombinant Follicle Stimulating Hormone

First Posted Date: 2017-04-18

Last Posted Date: 2017-11-07

Lead Sponsor: Cairo University

Target Recruit Count: 204

Registration Number: NCT03118830

Locations: 🇪🇬
Ahmed Maged, Cairo, Egypt

Luteal Phase Support in Insemination Cycles

Phase 4

Completed

Conditions: Infertility, Female

Interventions: Drug: Triptorelin

First Posted Date: 2017-04-14

Last Posted Date: 2020-01-27

Lead Sponsor: Tampere University Hospital

Target Recruit Count: 167

Registration Number: NCT03115307

Locations: 🇫🇮
Tampere University Hospital, Tampere, Finland

Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer

Phase 2

Conditions: Toxicity Due to Chemotherapy
Sarcoma
Osteosarcoma
Cancer
Lymphoma
Ewing Sarcoma

Interventions: Drug: Triptorelin (GnRHa) + Chemotherapy

First Posted Date: 2016-08-04

Last Posted Date: 2019-12-17

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 11

Registration Number: NCT02856048

Locations: 🇫🇷
AP-HP, Bicêtre Hospital, Le Kremlin Bicêtre, France

Comapring Luteal Phase Support in IVF Patients Who Are at High Risk for Developing OHSS

Not Applicable

Conditions: Infertility

Interventions: Drug: hCG luteal support
Drug: Decapeptyl

First Posted Date: 2016-07-11

Last Posted Date: 2016-07-12

Lead Sponsor: Meir Medical Center

Target Recruit Count: 50

Registration Number: NCT02827656

Modified Luteal Support for Frozen-Thawed Embryo Transfer - A Prospective Study

Phase 4

Conditions: Luteal Support
Embryo Transfer

Interventions: Drug: Choriogonadotropin alfa
Drug: Triptorelin acetate

First Posted Date: 2016-07-07

Last Posted Date: 2016-12-13

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 62

Registration Number: NCT02825290

Locations: 🇮🇱
Sheba medical center, Ramat Gan, Israel

Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer

Phase 4

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Lupron
Drug: Trelstar
Drug: Zoladex

First Posted Date: 2016-04-25

Last Posted Date: 2016-04-25

Lead Sponsor: Pharmatech

Target Recruit Count: 41

Registration Number: NCT02749825

Locations: 🇺🇸
Jazrawi-Atallah, P.C., Brooklyn, New York, United States
🇺🇸
Albemarle Urology Clinic, PA, Albemarle, North Carolina, United States
🇺🇸
Raj P. Chopra MD, PC, Bloomsburg, Pennsylvania, United States

and more 8 locations

Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)

Phase 2

Conditions: Prostate Cancer

Interventions: Drug: Bicalutamide
Drug: goserelin acetate
Drug: flutamide
Drug: leuprolide acetate
Drug: triptorelin
Procedure: Definitive Treatment

First Posted Date: 2016-04-19

Last Posted Date: 2020-07-07

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT02742675

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Effects of Sex Steroids on the Serotonin System

Phase 4

Conditions: Gender Dysphoria

Interventions: Drug: Cyproterone Acetate
Drug: Testosterone
Drug: Lynestrenol
Drug: Estradiol
Drug: Triptorelin acetate

First Posted Date: 2016-03-22

Last Posted Date: 2018-10-15

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 92

Registration Number: NCT02715232

Locations: 🇦🇹
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria

Management of Castration-Resistant Prostate Cancer with Oligometastases

Phase 2

Active, not recruiting

Conditions: Castration-resistant Prostate Cancer Patients with Oligometastases

Interventions: Drug: Leuprolide Acetate
Drug: Goserelin Acetate
Drug: Triptorelin
Drug: Enzalutamide
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2016-02-18

Last Posted Date: 2024-12-04

Lead Sponsor: Sir Mortimer B. Davis - Jewish General Hospital

Target Recruit Count: 102

Registration Number: NCT02685397

Locations: 🇨🇦
BC CANCER Vancouver, Vancouver, British Columbia, Canada
🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦
Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy